Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...

The Levy family is excited to be recognized as the 2025 New England Take Steps Honored Family, and Soliel as the Honored Hero ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Older adults with moderate to severe IBD can achieve remission with JAK inhibitors, according to a study presented at Crohn’s & Colitis Congress.

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...

Clinical trials help researchers studying chronic conditions answer important questions about the diseases and their treatment options. However, uncertainty about what to expect and a lack of ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...